MM-003: Pomalidomide and LoDex versus HiDex in Patients with Relapsed/Refractory MM and Renal Impairment or Adverse Cytogenetics


MM-003: Pomalidomide and LoDex versus HiDex in Patients with Relapsed/Refractory MM and Renal Impairment or Adverse Cytogenetics
Slides from presentations at ASCO 2013 and transcribed comments from a recent interview with Antonio Palumbo, MD (8/20/13)
Weisel KC et al. Pomalidomide + low-dose dexamethasone (POM + LoDex) vs high-dose dexamethasone (HiDex) in relapsed/refractory multiple myeloma (RRMM): MM-003 analysis of patients (pts) with moderate renal impairment (RI). Proc ASCO 2013;Abstract 8527.

Goldschmidt H et al. Pomalidomide + low-dose dexamethasone (POM + LoDex) vs high-dose dexamethasone (HiDex) in relapsed/refractory multiple myeloma (RRMM): Impact of cytogenetics in MM-003. Proc ASCO 2013;Abstract 8528.

Dr Palumbo is Chief of the Myeloma Unit in the University of Torino’s Division of Hematology in Torino, Italy.